Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Tenax Therapeutics (TENX) to $15 from $16 and keeps a Buy rating on the shares. The firm, which is updating its model following the company’s Q1 results, looks forward to the Phase 3 LEVEL readout in 2026. The firm believes this data will be “a major catalyst from which we see the potential for at least a 2x stock move from current levels,” the analyst added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics reports Q1 EPS (28c), consensus (41c)
- Tenax Therapeutics sees cash, equivalents funding company through 2027
- Tenax Therapeutics Advances Cardiopulmonary Therapies
- Tenax Therapeutics files to sell 4.14M shares of common stock for holders
- Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)